Whitehawk Therapeutics (WHWK) Insider Reeve Buys 38,040 Shares

Insider Buying and Selling at Whitehawk Therapeutics, Inc.

Emma Reeve joined a group of company insiders in acquiring shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) on June 12, 2026. The transaction involved 38,040 shares. This activity followed a pattern set by several colleagues on the same day who stepped up to buy identical blocks of stock in the clinical-stage oncology therapeutics firm.

Group Insider Buying Activity

The June 12 purchases brought multiple key names into the buying column. Mohammad Hirmand, Behzad Aghazadeh, Baiteng Zhao, Richard Maroun, Neil Desai, and Caley Castelein each acquired 38,040 shares of Whitehawk Therapeutics on that date. None of these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. This cluster of acquisitions follows earlier coverage highlighting insider transactions at the Morristown, New Jersey-based biotech firm.

Stock Price Levels and Moving Averages

Shares of Whitehawk Therapeutics traded near $4.10 around the time of the insider filings. The stock has moved within a 52-week range stretching from $1.82 to $5.50. It currently rests near its 50-day moving average of $4.29 while holding above its 200-day moving average of $3.71. The company carries a market capitalization of $230.3 million.

Wall Street Analyst Coverage and Targets

Analyst opinion on the biotech company remains broadly upbeat. On June 25, 2026, B. Riley Securities initiated coverage with a buy rating and a $10.00 price target. Later on July 13, 2026, Leerink Partners started coverage with an outperform rating and a $9.00 price target. Stifel also initiated coverage on October 1, 2026, with a buy rating and a $9.00 price target. The stock holds a consensus buy rating with a mean price target of $7.50 across six analyst opinions.

Overview of Operations

Whitehawk Therapeutics develops technologies to establish tumor biology for cancer treatments. The clinical-stage firm focuses on three next-generation antibody-drug conjugate portfolios designed to tackle various cancers. Formerly known as Aadi Bioscience, the company adopted its current name in August 2021 and employs 32 people.

What to Watch at Whitehawk Therapeutics, Inc.

Investors tracking Whitehawk Therapeutics will look toward the company's next scheduled earnings report on November 5, 2026, for further updates on its clinical pipeline and financial position. Future SEC filings will also show whether insiders continue adjusting their holdings as the drug developer advances its oncology treatments.